• Written informed consent and HIPAA authorization for release of personal health information.

• Age ≥ 18years at the time of consent.

• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 within 28 days prior to registration.

• Radiographically consistent with metastatic renal cell carcinoma (with subsequent pathologic confirmation of renal cell carcinoma with a clear cell component) OR histological/ cytological evidence of metastatic renal cell carcinoma with a clear cell component

• Measurable tumor in the kidney according to RECIST 1.1

• No prior therapy for metastatic renal cell carcinoma

• Demonstrate adequate organ function as defined in the protocol; all screening labs to be obtained within 14 days prior to registration.

• Females of childbearing potential must have a negative serum pregnancy test during screening, within 14 days of Cycle 1 Day 1. NOTE: Females are considered of child bearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are naturally postmenopausal for at least 12 consecutive months

• Females of childbearing potential and males must be willing to abstain from heterosexual activity or to use 2 forms of effective methods of contraception from the time of informed consent until 6 months after treatment discontinuation. The two contraception methods can be comprised of two barrier methods, or a barrier method plus a hormonal method.

⁃ As determined by the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study